Abstract:Abstract Background Crohn’s disease (CD) is an inflammatory bowel disease with chronic course and exacerbations. Diagnosis and follow-up are based on clinical activity, biomarkers, ileocolonoscopy and imaging techniques. Intestinal ultrasound (IUS) has been shown to have high sensitivity and specificity analyzing inflammatory activity in CD. The aim of our study is to correlate IUS parameters with clinical activity and biomarkers in CD. Methods Retrospective, observational, single-center study was designed. Adult patients with CD who underwent IUS between September 2020 and May 2021 were included. Exclusion criteria was exclusive colonic involvement. Examination was done by ultrasound machine (Hitachi Ascendus) with low frequency curved-array (1–5 MHz) and high-frequency linear-array (5–13 MHz) transducers. Examination assessed bowel wall thickness, mesenteric fat hypertrophy, lymph nodes, hyperemia on color Doppler flow measured as Limberg index and length of affected segment (cm). Clinical activity score for CD was assessed by Harvey Bradshaw index (HBI). Biomarkers parameters studied were C-reactive protein (CRP) and faecal calprotectin (FC). Results are shown as percentages, median and interquartile range (IQR). Data were analysed using Spearman′s correlation analysis Results 121 patients were included (median age 45.6 years (IQR 33.4 – 59.6), 56.2% female). 78.5% had ileal disease and 21.5% ileocolonic involvement. At the time of IUS 17.4% of patients were not taking any maintenance treatment, 13.2% were on azathioprine, 48.8% on anti-TNF (61% adalimumab; 39% infliximab) and 8.3% on ustekinumab. 85.1% patients had HBI <6, 14.1% had moderate activity. Median CRP level was 0.334 mg/dl (IQR 0.06–1.12), FC was 141 μg/g (IQR 35–386). Median wall thickening was 4.7 mm (range 4.1–5.6), 68.6% of patients had mesenteric fat hypertrophy and 73.55% had lymph nodes. Limberg index was 0 in 20.7%, 1 in 23.1%, 2 in 37.2% and 3 in 19% of patients. IUS determined treatment modification in 60.3% of cases: 19% started biological therapy, 15.7% changed biological target, 14.9% underwent intensification or reinduction of biological treatment, in 1.7%, treatment reduction was decided. The Spearman′s correlation between IUS parameters, clinical and biochemical markers is presented in Table 1. IUS parameters were significantly associated with faecal calprotectin and CRP level, specially Limberg Index and faecal calprotectin (r=0.56, p<0.05) and Limberg Index and CRP level (r= 0.38, p<0.05) (Figure 1 and 2). No correlation was observed between HBI and IUS parameters. Conclusion Through this study, significant correlation between IUS and biomarkers was observed in CD. IUS has been shown to be useful for monitoring CD activity in order to optimize patients′ treatment.

P400 Experience with the use of intestinal ultrasound and application of the Milan Ultrasound Criteria in Colombian patients with ulcerative colitis

P601 Intestinal ultrasound correlates with clinical, biochemical, endoscopic and histologic biomarkers in patients with Ulcerative Colitis: a cross-sectional study

P492 All intestinal ultrasound scores for ulcerative colitis (and IBUS-SAS) strongly correlate with endoscopic activity: a prospective study

P355 Correlation of Intestinal Ultrasound with histological activity in patients with Ulcerative Colitis

P472 A Real World Practice of Intestinal Ultrasound in the Monitoring of Disease Activity in Ulcerative Colitis

P691 Intestinal ultrasonography accuracy in the evaluation of patients with moderate to severe ulcerative colitis starting infliximab therapy

Four intestinal ultrasound scores and bowel wall thickness alone correlated well with pediatric ulcerative colitis disease activity

The prospective study of intestinal ultrasonography in the diagnosis and assessment of IBD activity

P042 Significant correlation between intestinal ultrasound and magnetic resonance enterography for assessing disease activity and complications in Crohn’s disease

P1031 Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis treated with upadacytynib

P310 Intestinal ultrasound as a tool to assess treatment response in patients with Inflammatory Bowel Diseases

P417 1 year follow-up of pediatric ulcerative colitis using intestinal ultrasound

P243 Relationship between intestinal ultrasound, fecal calprotectin and Harvey-Bradshaw Index in the assessment of infllamatory activity in Cronh′s Disease

Early Intestinal Ultrasound Predicts Clinical and Endoscopic Treatment Response and Demonstrates Drug-Specific Kinetics in Moderate-to-Severe Ulcerative Colitis

P248 The diagnostic accuracy of Intestinal ultrasound for assessing disease activity in the proximal ileum and jejunum in children with Crohn’s disease: Preliminary results of a prospective study

Correlation Between Ultrasound Consolidated Score and Simple Endoscopic Score for Determining the Activity of Crohn's Disease.

P295 Early sonographic improvement predicts the middle-term efficacy of molecular-targeted medications for Ulcerative Colitis

P484 Intestinal Ultrasound Can Detect Active Inflammation In Inflammatory Bowel Disease Patients Despite Combined Clinical And Biomarker Remission

Evaluation of Crohn's Disease Activity: Validation of a Segmental Simple Ultrasound Score in a Multicenter Study

P405 Intestinal ultrasound measures are highly correlated with small bowel Lewis score among patients with active Crohn’s disease

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests